Coherus BioSciences says it is “very pleased” with the progress of its Formycon-partnered Cimerli (ranibizumab-eqrn) biosimilar to Genentech’s Lucentis in the US, insisting that the company’s 190,000 doses shipped since launch and 30% volume share is “really important for ophthalmologists, because ophthalmologists have been burned time and again by novel agents that come on the market.”
“Cimerli has now accumulated over $125m in net annual revenue through Q4, and about 29% market share. It’s actually probably...






